The pharmaceutical company Lilly is known for their strong diabetes treatment pipeline. As the world’s first developer of insulin, Lilly has solidified its position in the field, introducing DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 analogues into its pipeline.

However, Lilly has transformed. It did not give up diabetes, the company just added more ‘weapons to its arsenal.’ From some point, the company began to exert its influence in the fields of cancer and autoimmune diseases.

In the lung cancer drug market, where the company had made no significant impact other than with ‘Alimta,’ Lilly released the VEGFR-inhibitor 'Cyramza,’ and also introduced the first-in-class RET-targe